Maurizio Del Poeta Selected Research

Cryptococcosis

1/2022	Three Models of Vaccination Strategies Against Cryptococcosis in Immunocompromised Hosts Using Heat-Killed Cryptococcus neoformans Δsgl1.
1/2021	Cryptococcus neoformans Δsgl1 Vaccination Requires Either CD4+ or CD8+ T Cells for Complete Host Protection.
1/2020	Fenbendazole Controls In Vitro Growth, Virulence Potential, and Animal Infection in the Cryptococcus Model.
1/2020	Animal Models of Cryptococcus neoformans in Identifying Immune Parameters Associated With Primary Infection and Reactivation of Latent Infection.
1/2020	FTY720 reactivates cryptococcal granulomas in mice through S1P receptor 3 on macrophages.
1/2019	Cryptococcus neoformans Glucuronoxylomannan and Sterylglucoside Are Required for Host Protection in an Animal Vaccination Model.
10/2017	Analysis of sphingolipids, sterols, and phospholipids in human pathogenic Cryptococcus strains.
1/2017	The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against Cryptococcus neoformans.
1/2016	Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis.
7/2015	The Granuloma Response Controlling Cryptococcosis in Mice Depends on the Sphingosine Kinase 1-Sphingosine 1-Phosphate Pathway.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maurizio Del Poeta Research Topics

Disease

22	Infections 01/2022 - 06/2006
17	Cryptococcosis 01/2022 - 03/2005
8	Mycoses (Diseases, Fungus) 01/2022 - 12/2010
3	Invasive Fungal Infections 11/2020 - 12/2015
3	Granuloma 01/2020 - 10/2007
2	Mitochondrial Diseases (Mitochondrial Disease) 10/2021 - 02/2021
2	COVID-19 10/2021 - 02/2021
2	Aspergillosis 01/2021 - 01/2020
2	Neoplasms (Cancer) 10/2020 - 06/2006
2	Starvation 01/2020 - 03/2011
2	Meningoencephalitis 06/2012 - 08/2005
2	Communicable Diseases (Infectious Diseases) 01/2010 - 06/2006
1	Galactosemias (Galactosemia) 01/2022
1	Headache (Headaches) 01/2022
1	Hypersensitivity (Allergy) 01/2022
1	Cryptococcal Meningitis 01/2022
1	Coinfection 10/2021
1	Sporotrichosis 02/2021
1	Relapsing-Remitting Multiple Sclerosis 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Sarcoma (Soft Tissue Sarcoma) 12/2014
1	Brain Diseases (Brain Disorder) 06/2012
1	Lymphoma (Lymphomas) 01/2009
1	Inflammation (Inflammations) 06/2006
1	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2006

Drug/Important Bio-Agent (IBA)

8	SphingolipidsIBA 01/2022 - 06/2006
7	LipidsIBA 02/2020 - 06/2006
6	Pharmaceutical PreparationsIBA 02/2021 - 01/2011
6	Glucosylceramides (Glucocerebrosides)IBA 01/2019 - 10/2007
5	VaccinesIBA 01/2022 - 01/2015
3	EnzymesIBA 01/2022 - 08/2005
3	Amphotericin B (Amphotericin)FDA LinkGeneric 02/2021 - 01/2017
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2005
2	Fingolimod Hydrochloride (FTY720)FDA Link 01/2022 - 01/2020
2	Fungal VaccinesIBA 01/2022 - 12/2015
2	Urea (Carbamide)FDA LinkGeneric 10/2021 - 02/2021
2	Secretory Phospholipases A2IBA 10/2021 - 02/2021
2	NitrogenIBA 10/2021 - 02/2021
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 01/2021 - 02/2020
2	AzolesIBA 01/2021 - 01/2016
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 03/2011
2	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 01/2020 - 07/2015
2	CeramidesIBA 01/2019 - 01/2012
2	sphingosine kinaseIBA 07/2015 - 05/2010
2	Virulence Factors (Pathogenicity Factors)IBA 01/2012 - 08/2005
1	thermozymocidin (myriocin)IBA 01/2022
1	Galactose (Galactopyranose)FDA LinkGeneric 01/2022
1	UTP-Hexose-1-Phosphate Uridylyltransferase (UTP Hexose 1 Phosphate Uridylyltransferase)IBA 01/2022
1	Ergosterol (Lumisterol)IBA 10/2021
1	Phospholipases (Phospholipase)IBA 02/2021
1	Itraconazole (Sporanox)FDA LinkGeneric 02/2021
1	Potassium Iodide (Pima)FDA Link 02/2021
1	aureobasidin AIBA 11/2020
1	Antineoplastic Agents (Antineoplastics)IBA 10/2020
1	GlycosidesIBA 02/2020
1	tau Proteins (tau Protein)IBA 01/2020
1	Sphingosine-1-Phosphate ReceptorsIBA 01/2020
1	Therapeutic UsesIBA 01/2020
1	siponimodIBA 01/2020
1	Antifungal AgentsIBA 01/2020
1	FenbendazoleIBA 01/2020
1	Polysaccharides (Glycans)IBA 01/2019
1	GlycolipidsIBA 01/2019
1	GlycosphingolipidsIBA 01/2018
1	Flucytosine (Ancobon)FDA Link 01/2017
1	EchinocandinsIBA 01/2016
1	PolyenesIBA 01/2016
1	CytokinesIBA 07/2015
1	CholesterolIBA 12/2014
1	CyclodextrinsIBA 12/2014
1	Immunoglobulin M (IgM)IBA 06/2012
1	AntigensIBA 06/2012
1	ceramide glucosyltransferaseIBA 01/2011
1	CollagenIBA 05/2010
1	Complement System Proteins (Complement)IBA 01/2009
1	LaccaseIBA 08/2005
1	Melanins (Melanin)IBA 08/2005
1	DEAD-box RNA HelicasesIBA 03/2005

Therapy/Procedure

2	Lasers (Laser) 01/2011 - 12/2010
1	Catheters 01/2022
1	Therapeutics 01/2020
1	Organ Transplantation 06/2012